2023-04-28 16:00Financial Performance - Total operating revenue for Q1 2023 reached ¥6,477,062,887.66, an increase of 35.69% compared to ¥4,773,517,945.43 in the same period last year[3] - Net profit attributable to shareholders was ¥2,156,742,527.33, reflecting a growth of 65.58% from ¥1,302,527,153.83 year-on-year[3] - Basic earnings per share increased to ¥0.27, up 58.82% from ¥0.17 in the previous year[3] - Total profit for Q1 2023 was CNY 2,838,034,953.16, an increase of 55.7% compared to CNY 1,821,456,176.17 in Q1 2022[18] - Net profit attributable to shareholders of the parent company reached CNY 2,156,742,527.33, up 65.7% from CNY 1,302,527,153.83 in the same period last year[18] - Basic and diluted earnings per share were both CNY 0.27, compared to CNY 0.17 in Q1 2022, reflecting a 58.8% increase[18] Asset and Liability Overview - Total assets as of the end of Q1 2023 amounted to ¥664,447,965,942.89, a 7.65% increase from ¥617,256,282,027.40 at the end of the previous year[3] - Total liabilities rose to ¥536,683,152,238.43, compared to ¥492,463,441,551.26, marking an increase of 9.0%[16] - Owner's equity totaled ¥127,764,813,704.46, up from ¥124,792,840,476.14, indicating a growth of 2.4%[16] - The company reported a total borrowing balance of 3,461.87 billion yuan as of March 31, 2023, with a cumulative increase of 319.79 billion yuan, representing 25.63% of the net assets as of December 31, 2022[12] Investment and Income - Investment income for Q1 2023 was ¥1,504,600,613.70, a significant recovery from a loss of ¥571,686,079.49 in the same period last year[7] - The fair value change income was ¥212,734,947.58, a notable improvement from a loss of ¥490,448,143.88 in the previous year[8] - Net interest income was ¥937,302,735.92, with interest income of ¥3,460,267,569.79 and interest expenses of ¥2,522,964,833.87[17] - The net income from commission and fee-based services was ¥3,721,428,628.85, down from ¥4,259,408,663.73, reflecting a decrease of 12.7%[17] Cash Flow Analysis - Cash flow from operating activities showed a net outflow of ¥4,582,031,552.90, compared to a net inflow of ¥13,721,694,703.99 in the same period last year[8] - Total cash inflow from operating activities was CNY 47,907,559,435.46, down 17.6% from CNY 58,198,678,471.47 in Q1 2022[19] - Cash outflow from operating activities totaled CNY 52,489,590,988.36, an increase of 18% compared to CNY 44,476,983,767.48 in the same period last year[20] - Cash flow from investment activities generated a net inflow of CNY 3,302,689,070.77, down from CNY 4,246,862,881.19 in Q1 2022[20] - The cash and cash equivalents at the end of the period stood at CNY 147,745,541,864.16, compared to CNY 138,963,413,452.33 at the end of Q1 2022[20] Shareholder Information - As of March 31, 2023, the total number of ordinary shareholders is 244,409, with 22.31% held by Hong Kong Central Clearing Limited, representing 1,700,147,050 shares[9] - Jilin Aodong Pharmaceutical Group holds 16.43% of shares, totaling 1,252,297,867 shares, while Liaoning Chengda holds 16.40%, totaling 1,250,154,088 shares[9] - The company has no pledged, marked, or frozen shares among the top ten shareholders[9] - The total number of shareholders with restored voting rights for preferred shares is not applicable[11] Business Operations and Strategy - The company has 25 branches and 315 securities business departments across 31 provinces, municipalities, and autonomous regions in China[11] - The company received approval from the China Securities Regulatory Commission to conduct index options market-making business[12] - The company has restructured its retail business organization, renaming the retail management headquarters to "Wealth Management and Brokerage Business Headquarters" and merging departments for efficiency[12] - The company plans to continue expanding its market presence and investing in new technologies to enhance service offerings and operational efficiency[17] Regulatory and Compliance - The company maintains a stable financial condition, with all debts being repaid on time, and the new borrowings will not adversely affect its operational status or debt repayment capability[12] - The company is cooperating with the China Securities Regulatory Commission regarding an investigation related to its sponsorship of a non-public stock issuance in 2018[12]